- The disease
- Acute myeloid leukaemia (AML) is a cancer of the blood and bone marrow in which abnormal white blood cells accumulate rapidly, crowding out normal blood cells. It is the most common acute leukaemia in adults and is associated with high rates of relapse after initial treatment. Patients whose disease returns or does not respond to standard chemotherapy have limited treatment options and poor outcomes.
- What the asset is trying to do
- OmniCAR is described by Prescient Therapeutics as a universal adapter CAR-T (chimeric antigen receptor T-cell) platform, licensed from the University of Pennsylvania and the University of Oxford, with validation studies stated to be ongoing (per Prescient Therapeutics ASX disclosures). Unlike conventional CAR-T products, which are engineered to recognise a single fixed target, a universal adapter platform is designed to allow the same CAR-T cells to be redirected toward different tumour targets by pairing them with a separate targeting molecule. The specific antigen target or targets being pursued in AML have not been publicly disclosed.
- What the trial is measuring, and why it matters
- No clinical trial has been registered for OmniCAR in AML as of the data provided, and no endpoints have been publicly specified. When a first-in-human trial is initiated, typical early-phase CAR-T studies measure safety (dose-limiting toxicities), tolerability, and preliminary signals of anti-tumour activity such as complete remission rate. once trial registration details are available.
- Efficacy benchmarks in this setting
- In relapsed or refractory AML, approved therapies vary by disease subtype. For example, the CD33-directed antibody-drug conjugate gemtuzumab ozogamicin achieved a complete remission rate of approximately 26.2% as monotherapy in a pivotal study of patients with relapsed/refractory AML (per MyAML US prescribing information / Pfizer). The IDH1 inhibitor ivosidenib achieved a complete remission plus complete remission with partial haematologic recovery rate of 21.5% in IDH1-mutated relapsed/refractory AML (per Tibsovo US prescribing information). OmniCAR in AML is at a preclinical stage and has no clinical efficacy data; any future early-phase figures would not be statistically comparable to these approved-therapy benchmarks.
- Commercial context
- No CAR-T therapy has been approved specifically for AML in any major market as of the data provided. OmniCAR in AML is preclinical, and no clinical trial has been registered for this specific application. Prescient Therapeutics has stated that OmniCAR is licensed from the University of Pennsylvania and the University of Oxford, with validation studies ongoing (per ASX disclosures). The company's active clinical programmes involve PTX-100, not OmniCAR; OmniCAR in AML is therefore not Prescient's lead clinical asset at this time.